Sign In
Buy WHWK
$3.91
+0.120 (+3.17%)
At Close: Jul 21, 2026
Whitehawk Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
08:00am, Thursday, 06'th Nov 2025
MORRISTOWN, N.J. , Nov. 6, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently
PTK7 is the third most highly expressed tumor marker among clinically validated and emerging ADC targets, present in ~70% of tumors PTK7 expression is stable across histologic subtype, disease stage a
Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research
08:30am, Thursday, 16'th Oct 2025
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a multi-year collaboration with Whitehawk Therap
Whitehawk Therapeutics to Participate in Upcoming Investor Conferences
08:00am, Tuesday, 02'nd Sep 2025
MORRISTOWN, N.J. , Sept. 2, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficientl
